Polymeric long-acting drug delivery systems (LADDS) for treatment of chronic diseases: Inserts, patches, wafers, and implants

Hamdy Abdelkader; Zeinab Fathalla; Ali Seyfoddin; Mojtaba Farahani; Thilini Thrimawithana; Ayman Allahham; Adam W G Alani; Ali A Al-Kinani; Raid G Alany

doi:10.1016/j.addr.2021.113957

Polymeric long-acting drug delivery systems (LADDS) for treatment of chronic diseases: Inserts, patches, wafers, and implants

Adv Drug Deliv Rev. 2021 Oct:177:113957. doi: 10.1016/j.addr.2021.113957. Epub 2021 Sep 1.

Authors

Hamdy Abdelkader¹, Zeinab Fathalla², Ali Seyfoddin³, Mojtaba Farahani⁴, Thilini Thrimawithana⁵, Ayman Allahham⁵, Adam W G Alani⁶, Ali A Al-Kinani⁷, Raid G Alany⁸

Affiliations

¹ Pharmaceutics Department, Faculty of Pharmacy, Minia University, Minia, Egypt; Department of Pharmaceutics, Faculty of Pharmacy, Deraya University, New Minia City, Minia, Egypt.
² Pharmaceutics Department, Faculty of Pharmacy, Minia University, Minia, Egypt.
³ Drug Delivery Research Group, Faculty of Health and Environmental Sciences, School of Science, Auckland University of Technology, New Zealand.
⁴ Department of Biomedical Engineering, Amirkabir University of Technology, Tehran, Iran.
⁵ Discipline of Pharmacy, School of Health and Biomedical Sciences, RMIT University, Melbourne, VIC, Australia.
⁶ Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Moody Avenue, RLSB, Portland, OR, United States; Biomedical Engineering Department, Oregon Health & Science University, 2730 S. Moody Avenue, RLSB, Portland, OR, United States; Knight Cancer Institute, Oregon Health & Science University, 2730 S. Moody Avenue, RLSB, Portland, OR, United States.
⁷ Drug Discovery, Delivery and Patient Care Theme (DDDPC), Faculty of Science, Engineering and Computing, Kingston University London, Penrhyn Road, Kingston upon Thames, UK. Electronic address: a.alkinani@kingston.ac.uk.
⁸ Drug Discovery, Delivery and Patient Care Theme (DDDPC), Faculty of Science, Engineering and Computing, Kingston University London, Penrhyn Road, Kingston upon Thames, UK; School of Pharmacy, The University of Auckland, Auckland, New Zealand. Electronic address: r.alany@kingston.ac.uk.

PMID: 34481032
DOI: 10.1016/j.addr.2021.113957

Abstract

Non-oral long-acting drug delivery systems (LADDS) encompass a range of technologies for precisely delivering drug molecules into target tissues either through the systemic circulation or via localized injections for treating chronic diseases like diabetes, cancer, and brain disorders as well as for age-related eye diseases. LADDS have been shown to prolong drug release from 24 h up to 3 years depending on characteristics of the drug and delivery system. LADDS can offer potentially safer, more effective, and patient friendly treatment options compared to more invasive modes of drug administration such as repeated injections or minor surgical intervention. Whilst there is no single technology or definition that can comprehensively embrace LADDS; for the purposes of this review, these systems include solid implants, inserts, transdermal patches, wafers and in situ forming delivery systems. This review covers common chronic illnesses, where candidate drugs have been incorporated into LADDS, examples of marketed long-acting pharmaceuticals, as well as newly emerging technologies, used in the fabrication of LADDS.

Keywords: 3D printing; Brain disorders; Cancer; Diabetes; Eye diseases; In situ forming implants; Microneedle; PLGA; Wafer.

Publication types

Review

MeSH terms

Animals
Chronic Disease / drug therapy*
Dosage Forms
Drug Delivery Systems*
Humans
Polymers / administration & dosage*

Substances

Dosage Forms
Polymers